Skip to main content

editorial

. 2010 Oct;7(4):335–337. doi: 10.1016/j.nurt.2010.08.003

Targeting glia for treatment of neurological disease

David A Rempe ^1,^✉, Maiken Nedergaard ²

PMCID: PMC5084296 PMID: 20880498

The content is available as a PDF (57.8 KB).

References

1.Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615–622. doi: 10.1038/nn1876. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441–445. doi: 10.1038/nm1387. [DOI] [PubMed] [Google Scholar]
3.Ehrenreich H, Weissenborn K, Range H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647–e656. doi: 10.1161/STROKEAHA.109.564872. [DOI] [PubMed] [Google Scholar]
4.Asano T, Mori T, Shimoda T, et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord. 2005;4:127–142. doi: 10.2174/1568007053544084. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES